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Blood buffy coatA major goal of current clinical research in Huntington's disease (HD) has been to identify preclinical and
manifest disease biomarkers, as these may improve both diagnosis and the power for therapeutic trials.
Although the underlying biochemical alterations and the mechanisms of neuronal degeneration remain
unknown, energy metabolism defects in HD have been chronicled for many years. We report that the brain
isoenzyme of creatine kinase (CK-BB), an enzyme important in buffering energy stores, was signiﬁcantly
reduced in presymptomatic and manifest disease in brain and blood buffy coat specimens in HDmice and HD
patients. Brain CK-BB levels were signiﬁcantly reduced in R6/2 mice by ∼18% to ∼68% from 21 to 91 days of
age, while blood CK-BB levels were decreased by ∼14% to ∼44% during the same disease duration. Similar
ﬁndings in CK-BB levels were observed in the 140 CAG mice from 4 to 12 months of age, but not at the
earliest time point, 2 months of age. Consistent with the HD mice, there was a grade-dependent loss of brain
CK-BB that worsened with disease severity in HD patients from ∼28% to ∼63%, as compared to non-diseased
control patients. In addition, CK-BB blood buffy coat levels were signiﬁcantly reduced in both premanifest
and symptomatic HD patients by ∼23% and ∼39%, respectively. The correlation of CK-BB as a disease
biomarker in both CNS and peripheral tissues from HD mice and HD patients may provide a powerful means
to assess disease progression and to predict the potential magnitude of therapeutic beneﬁt in this disorder.Clinical Center, New England
ited States. GRECC Unit 182B,
A 01730, USA. Tel.: +1 781 687
B.V.Published by Elsevier B.V.1. Introduction
Huntington's disease (HD) is an autosomal dominant and fatal
neurological disorder caused by an expanded trinucleotide CAG
repeat in the gene coding for the protein, huntingtin. No proven
treatment to prevent the onset or to delay the progression of HD
currently exists. A major goal of current clinical research in HD is to
develop biomarkers that detect andmonitor progression of preclinical
and early manifest disease in order to help facilitate clinical trials.
Despite great progress, a direct causative pathway from the HD
gene mutation to neuronal dysfunction and death has not yet been
established. There is strong evidence from human and animal studies,
however, suggesting that one mechanism by which mutant hunting-tin and its fragments trigger both damaging and compensatory
molecular processes is via mitochondrial damage and energy
depletion, ultimately leading to increasingly fragile neurons suscep-
tible to more generic stresses and neuronal death [1]. Energetic
defects in HD subjects have been chronicled for many years and
include primary alterations of electron transport chain complexes
[2–8]. A secondary consequence of the gene defect causing impaired
energy metabolism is mitochondrial dysfunction. N-terminal hun-
tingtin fragments may directly impair mitochondrial function, leading
to increased oxidative damage [7]. Strong evidence also exists for
early metabolic deﬁcits and energy depletion in HD subjects, as early
weight loss prior to the onset of chorea [9], reduced glucose utilization
and hypometabolism in both presymptomatic and symptomatic HD
patients prior to striatal atrophy [10,11], and magnetic resonance
spectroscopy showing a signiﬁcant decrease in the phosphocreatine
to inorganic phosphate ratio in resting muscle and increased lactate
concentrations in the cerebral cortex [12]. It is of interest to note that
in patients with other trinucleotide repeat diseases, such as
spinocerebellar ataxias, there is a commonmechanism linking energy
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substantial evidence in experimental models of HD, suggesting an
important interplay between energy metabolism defects and aberrant
mitochondrial function in the pathogenesis of HD [15].
Creatine kinase (CK), an enzyme that rapidly catalyses the
conversion of creatine and consumes adenosine triphosphate to
create phosphocreatine and adenosine diphosphate, is an important
enzyme in producing and buffering energy stores [16]. There are two
subunits, B (brain type) and M (muscle type), with three different
circulating isoenzymes, CK-MM, CK-BB and CK-MB [16,17]. In
addition, there are two mitochondrial creatine kinase isoenzymes,
the ubiquitous (uMT-CK) and sarcomeric form. ATP, the key energetic
molecule, is tightly coupled to phosphocreatinemetabolism via the CK
enzyme system [16]. As such, CK plays a central role in energy transfer
in cells with high and ﬂuctuating energy requirements and is critically
vital in energy homeostasis. CK isoenzymes are highly susceptible to
oxidative stress [18], an important pathophysiological mechanism
associated with HD [19]. Of note, CK-BB is speciﬁc to inhibitory
neurons in the brain [20], those that selectively degenerate in HD [21].
While CKactivity has been reported inmoderate-late stageR6/2mice
[22], there are no studies that examine the early and progressive loss of
CK in central nervous systemandperipheral blood tissue specimens from
HD patients, with correlation in HD mice. We investigated CK-BB in
premanifest and symptomatic human HD patients with parallel studies
in the fragment R6/2 and the full-length 140 CAG knock-in models of
HD mice. We hypothesize that decreased brain energetics in HD may
be the result of reduced activity of the CK system and that early loss of
CK-BB may be an important unrecognized biomarker of disease.
2. Methods
2.1. R6/2 and 140 CAG mouse samples
Male transgenic fragment R6/2 and heterozygous full-length 140
CAG knock-in mice were obtained from established colonies at the
Bedford VAMedical Center andwere backcrossed with B6CBA females
from Jackson Laboratory (Bar Harbor, ME). The offspring were
genotyped using a PCR assay on tail DNA. Cohort homogeneity is
essential in testing potential hypotheses in murine models of disease.
Minimizing measurement variability increases the power to detect
differences. Mice were randomized from approximately 50 litters all
within 4 days of the same age from the same 'f' generation of R6/2 and
140 CAG mice. Any mice that had altered CAG repeats outside of the
expected range from both R6/2 mice (148–153 CAG repeats) and 140
CAGmice (138–143 CAG repeats) were excluded from the study, since
increased or reduced CAG repeats outside of the expected range may
result in increased variability in disease severity [23]. Mice were
equally distributed according to weight and parentage within each
cohort (n=10) of R6/2 and 140 CAG mice and littermate age-
matched wild type control mice. Since others and we have not
observed gender differences in the R6/2 and 140 CAGHDmice, female
mice were used in the experimental paradigms. The mice were
housed ﬁve in each cage under standard conditions with ad libitum
access to food andwater. Mice were identiﬁed by a randomly assigned
code so that the studies were performed blind as to the genetic
identity of the mice. The mice were handled under the same
conditions by one investigator. Groups (n=10) of mice were
euthanized by decapitation at 21, 30, 63, and 91 days of age from
R6/2 mice and at 2, 4, 8, and 12 months of age from 140 CAG mice.
This allows for an analysis across the clinical spectrum of disease
severity in each HD mouse model from clinically premanifest time
points, disease onset, mid stage disease, and late stage disease. Fresh
blood (0.3–0.5 ml) was collected in Eppendorf tubes containing
0.05 ml heparin, immediately centrifuged to separate blood compo-
nents, frozen in liquid nitrogen (−80°C), and stored in a −80°C
freezer for subsequent analysis. Brains were rapidly dissected,quartered, placed in Eppendorf tubes, ﬂash frozen in liquid nitrogen
(−80°C), and stored at−80°C. From decapitation to freezing of brain
tissue and blood specimens took nomore than 70 swith a team of four
investigators. Our experience has been that longer dissection times
result in increasing variability in the data that precludes signiﬁcance.
Groups (n=10) of R6/2 and 140 CAGmice and littermatewild-type
control mice from the late stage time points were deeply anesthetized
and transcardially perfused with 2% buffered paraformaldehyde
(100 ml), with care to avoid the introduction of any perfusion artifact.
Brains were removed, cryoprotected, and serially sectioned (50 μm).
Serial cut mouse tissue sections were subsequently immunostained for
CK-BB. All of the experiments were performed in accordance with the
National Institutes of Health Guide for the Care and Use of Laboratory
Animals and were approved by both the Veterans Administration and
Boston University Animal Care Committees.
2.2. Human samples
Postmortem striatal tissue specimens from 22 adult-onset HD
patients (ﬁve Grade 2 cases, nine Grade 3 cases, and eight Grade 4
cases; mean age of death, 67.1 years; range, 59–70 years) and eight
age-matched patients without any known neurological sequela
(mean age, 68.9 years; range 60–78 years) were dissected fresh and
rapidly quenched in liquid nitrogen (−80°C). Brain tissue specimens
were collected at the Bedford Veterans AdministrationMedical Center
Brain Tissue Archive and the Boston University Alzheimer's Disease
Center. The postmortem intervals did not exceed 18 h (mean time,
12.2 h; range, 4–14 h) and were similar for controls and HD patients.
CAG repeat length analysis was performed on the HD specimens
(mean number of CAG repeats, 44.2). The range of CAG repeats in the
adult-onset HD patients was 41–46. Each HD patient had been
clinically diagnosed based on known family history and phenotypic
symptoms of HD. The diagnosis of HD was conﬁrmed by neuropath-
ological examination and graded by severity [24]. Blood was collected
into heparin tubes and processed to obtain buffy coats from 30 HD
subjects and 20 controls and ﬂash frozen in situ undisturbed by
pipetting. The blood samples were collected for the REVEAL-HD
biomarker project at the Massachusetts General Hospital Hunting-
ton's Disease Center (HDR and SMH) under an IRB approved protocol.
Subjects included presymptomatic individuals known to possess the
genetic mutation causing HD, individuals with symptomatic HD, and
spousal controls.
As with the mouse samples, paraformaldehyde–lysine–periodate
ﬁxed striatal tissue blocks from 10 Grade 3 and 8 age-matched non-
neurological controls were rinsed in 0.1 M sodium phosphate buffer,
and placed in cold cryoprotectant in increasing concentrations of 10%
and 20% glycerol, 2% DMSO solution for 24–36 h. Frozen serial sections
of the striatal tissue blocks from the anterior commissure to the
rostral extent of the globus pallidus were cut at 50-μm intervals in the
coronal plane and placed within a six-well collection container. The
cut sections were stored in 0.1 M sodium phosphate buffer with 0.08%
sodium azide at 4 °C for subsequent immunocytochemistry using a
CK-BB antibody (1:500, Abcam).
2.3. Western blot analysis, brain
Brain lysates from both human patients and HD mice were
obtained by fractionating striatal tissue samples in 100 mM Tris (pH
7.4) buffer containing 1% Triton-X 100,150 mM NaCl, 1 mM sodium
orthovanadate, 5 mM sodium ﬂuoride, 3 mM PMSF, 3 mM DTT,
0.5 µg/ml leupeptin, and 10 µg/ml aprotinin. Thirty micrograms of
protein from tissue lysates from the medial caudate nucleus in
patients and the left frontal neostriatum in HD mice was electro-
phoresed under reducing conditions on 8% polyacrylamide gels.
Proteins were transferred to a nitrocellulose membrane (Bio-Rad,
Hercules, CA). Nonspeciﬁc binding was inhibited by incubation in
Table 1
Data analysis of brain and blood samples from R6/2 HD mice measuring Ck-BB levels.
Days Brain Blood
R6/2 ± WI ± pb0.05 R6/2 ± WI ± pb0.05
21 days 0.613 0.035 0.752 0.029 0.047 0.447 0.033 0.522 0.023 0.047
30 days 0.688 0.051 0.83 0.021 0.013 0.456 0.041 0.54 0.021 0.022
42 days 0.564 0.059 0.85 0.018 0.001 0.433 0.053 0.581 0.018 0.017
63 days 0.331 0.047 0.946 0.038 0.001 0.398 0.061 0.632 0.038 0.001
91 days 0.287 0.038 0.912 0.021 0.001 0.346 0.057 0.617 0.026 0.001
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0.1% Tween 20) containing 5% nonfat dried milk for 0.5 h. Primary
antibodies against CK-BB isoenzyme (1:1000, Abcam, USA) were
diluted at 1:1000 in TBST with 1% milk and exposed to membranes
overnight at 4 °C. The membrane was washed twice in TBS-T 10 min
each, incubated in secondary antibodies (1:3000 goat anti rabbit for
CK-B) and 1:5000 goat anti mouse for alpha tubulin), and washed
three times in TBS-T. Immunoreactive proteins were detected
according to the enhanced chemiluminescence protocol (Pierce
Biotechnology, Rockford, IL). Results were standardized to alpha
tubulin and analyzed using NIH Image.2.4. Dot blot analysis, buffy coat
Buffy coat samples from both patients and mice were analyzed for
CK-BB. The dissection of blood buffy coats is critical to the success of
the method and must be precise. Introducing serum or RBCs within
the sample alters the results, causing increased variability and
reduced signiﬁcance. Tissue samples were placed in 300 µl Tris lysis
buffer (pH 7.4) containing 3.5 mM NaCl, 0.5% EDTA, 2.5 mM NP40,
10 µg/ml NaVO4, and 200 mM PMSF. Proteins were transferred to a
nitrocellulose membrane (Bio-Rad, Hercules, CA), with light vacuum
applied to the membrane for 1 h in a dot blot apparatus. The
membrane was rinsed in TBS-T for 10 min, blocked with 5% milk in
TBS-T and 1:1000 sodium azide for 2 h at room temperature and then
incubated with primary antibody overnight at 4 °C. The membrane
was washed twice in TBS-T 10 min each, incubated in secondary
antibodies (1:3000 goat anti rabbit for CK-BB and 1:5000 goat anti
mouse for alpha tubulin) ,and washed three times in TBS-T, incubated
in chemiluminescent reagent 5 min, blotted, exposed to ﬁlm, and
developed. The optical density of immunoblots was measured using a
computer-based image analysis system (NIH Image) and standardized
to alpha tubulin. Densitometric analysis was performed with the
experimenter (JK and RJF) blinded to disease conditions on multiple
rendered images. Of interest to note is that hospital lab testing for CK
is not speciﬁc for isoenzyme type and measures total enzyme activity.Fig. 1.Western and dot blot analyses of brain and blood from R6/2 HDmice through the
spectrum of disease at a premanifest stage (21 days), onset (30 days), and though early
(42 days), moderate (63 days), and end stage disease (91 days). There were signiﬁcant
differences between mutant and littermate control mice at each disease stage, to
include premanifest disease (Table 1). Blots are shown under each time point with
alpha tubulin controls.2.5. Behavioral testing (open ﬁeld testing)
Behavioral testing for 140 CAGmice was performed during the light
phase of the diurnal cycle since thesemice are sufﬁciently active during
that time. Measurements were made for 30 min after 15 min of
acclimation to the box (Opto-Varimex Unit, Columbus Instruments,
Columbus, OH, USA). Counts of horizontal and vertical motion activity
were monitored and quantitative analysis of locomotor activity and
rearing were assessed. The open ﬁeld box was cleaned before testing
each mouse. Each 30 min of testing were analyzed as three periods of
10-min intervals to study the inﬂuence of novelty and measured
behavior. The position of the cage in the array was kept constant
throughout testing. Any beam interruptionwas recorded and processed
by the Auto-Track System (ATS) software. The ATS software recorded
four separate measures: total ambulatory counts; total resting time,ambulatory time, and total distance traveled. Mice were coded and
investigators were blinded to the genotype and analysis.
2.6. Immunocytochemistry
Immunohistochemical localization of the CK-BB antibody (1:500,
Abcam, USA) was performed by using a conjugated second antibody
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preincubated in an absolute methanol and 0.3% hydrogen peroxide
solution for 30 min, washed (three times) in PBS (pH 7.4) for 10 min
each, placed in 10% normal goat serum (GIBCO) for 1 h, incubated
free-ﬂoating in primary antiserum at room temperature for 12–18 h
(all dilutions of primary antisera above included 0.08% Triton X-100
and 2% normal goat serum), washed (three times) in PBS for 10 min
each, placed in horse radish peroxidase-conjugated goat anti-rabbit IgG
(1:300 in PBS, Boehringer Mannheim, Indianapolis) or goat anti-mouse
IgG (1:300 in PBS, BoehringerMannheim), washed (three times) in PBS
for 10 min each, and reactedwith 3,3'-diaminobenzidineHCl (1 mg/ml)
in Tris–HCl buffer with 0.005% hydrogen peroxide. Speciﬁcity for the
antisera used in this study was examined in each immunochemical
experiment to assistwith interpretation of the results. This examination
was accomplished by omission of the primary and secondary antibodies
to determine the amount of background generated from the detection
assay.2.7. Fluorescent immunocytochemistry
Combined immunoﬂuorescence staining for GFAP and CK-BB was
performed on human striatal HD and normal control tissue speci-
mens. Striatal sections were incubated with rabbit anti-CK-BB
antibody (1:500, Abcam, USA) and mouse ant-GFAP antibody
(1:500, Chemicon, USA) in Tris–HCl buffer containing 0.3% Triton
X-100 for 24–72 h at 4 °C. Sections were then rinsed 3 times in PBS,
incubated in the dark with goat anti-rabbit Cy3 conjugate (1:200,
Jackson Labs, USA) and goat anti-mouse FITC conjugate (1:200,
Vector, USA) for 2 h at 20 °C. After rinsing three times in PBS, sections
were wet-mounted and coverslipped with 50% glycerol. Identical
microscopic ﬁelds were immediately photographed with a Nikon
Eclipse E800 ﬂuorescent microscope, delineating the location of GFAP
and CK-BB immunoreactivities within the same striatal section. The
ﬁelds were merged and colocalization was analyzed.Fig. 2. CK-BB immunohistochemistry of brain sections through anterior neostriatum at the lev
reduced in the R6/2 mutant mouse (B), in comparison to the wild type littermate control (
reduction in CK-BB immunoreactivity in themutant R6/2mouse (D)within both the neuropi
control mouse (C). Magniﬁcation bar in A is 2 mm. Magniﬁcation bar in D is 100 μm.2.8. Analysis
Multiple data sets were generated for each premanisfest and
manifest CK-BB biomarker proﬁle in mice and human subjects. Interval
scale data involving multiple groups were analyzed using ANOVA and
repeated measures of ANOVA, with multiple comparisons performed
using Fishers least signiﬁcant difference test. This data was correlated
and explored together from both the human and mouse proﬁles.
Statistical analyses of biomarker data focused on the differences
between groups and changes in the values of the biomarkers over
time with clinical measures of disease progression.3. Results
An analysis of R6/2 and 140 CAG HD mice showed a signiﬁcant
reduction in CK-BB levels in both brain and blood buffy coat samples
that were disease severity dependent in each mouse model. In R6/2
HD mice, brain levels of CK-BB were signiﬁcantly reduced in
premanifest diseased mice at 21 days by 18.5% (Table 1, Fig. 1).
There was an increasing loss of CK-BB levels through early, moderate,
and severe disease stages through 91 days of age, reaching a 68.5% loss
of brain CK-BB levels, as compared to littermate wild type control
mice (Table 1, Fig. 1). Consistent with a disease-dependent loss of
brain CK-BB, signiﬁcant reductions in CK-BB were observed in blood
buffy coat samples in presymptomatic mice and throughout disease
progression (Table 1, Fig. 1). The loss of CK-BB in blood samples was
not as great as that observed in brain samples and ranged from 14.4%
in premanifest diseased R6/2 mice to 43.9% in severe stage disease at
91 days. Immunohistological studies of cut brain tissue sections at the
level of the neostriatum showed parallel changes in CK-BB loss that
wasmost apparent at 91 days, with reduced immunoreactivity in both
the neuropil and cytoplasm of neurons (Fig. 2).
In contrast, CK-BB levels in both brain and blood buffy coat tissue
samples were not signiﬁcantly reduced at the earliest time pointel of the anterior commissure in R6/2mice at 91 days. Gross CK-BB immunoreactivity is
A). Higher magniﬁcation of the neostriatum from each tissue section shows a marked
l and the cytoplasm of striatal neurons (arrows), as compared to thewild type littermate
Fig. 3.Western and dot blot analyses of brain and blood from 140 CAG HDmice through
the spectrum of disease at a premanifest stage (2 months), onset (4 months), though
early (6 months), moderate (8 months), and severe disease (12 months). There were
signiﬁcant differences between mutant and littermate control mice at each disease
stage starting a 4 months of age (Table 2). Blots are shown under each time point with
alpha tubulin controls.
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control mice. Signiﬁcant losses of brain CK-BB levels, however, were
present at 4-, 6-, 8-, and 12-month time points in a severity of disease-
dependent manner, ranging from 18.9% to 41.9% (Table 2, Fig. 3).
Congruous with brain CK-BB levels, CK-BB levels in blood buffy coat
samples were also signiﬁcantly reduced with increased disease
severity and similar percentile levels of loss from 17.8% to 41.4%
(Table 2, Fig. 3). While previous hyperkinetic motor activity has been
observed at 1 month of age and hypoactivity at 4 months [25], our
open ﬁeld analyses in 140 CAG mice of distance traveled, ambulatory
counts, resting time, and ambulatory time showed signiﬁcant
differences from only the 3 month time point onward (pb0.5), in
comparison to littermate control mice (Fig. 4), suggesting that the
2-month time point may be a clinically premanifest time point.
Immunostaining of 140 CAGmice tissue sections using CK-BB antisera
conﬁrmed CK-BB loss in the brain, showed reduced gross CK-BB
immunoreactivity and a loss of CK-BB within the neuropil and in the
cytoplasm of neurons (Fig. 5).
We evaluated CK-BB in human HD brain and blood buffy coat
specimens by using well-deﬁned HD stages of disease. CK-BB was
reduced in a grade-dependent manner in caudate nucleus specimens
of all grades of severity (Grades 2–4) from HD patients, as compared
to non-diseased control tissue specimens (Fig. 6). Densitometric
analysis showed signiﬁcantly reduced differences between CK-BB
levels with increasing grade of severity [24] (Control vs. G2: 27.6%,
pb0.04; Control vs. G3; 53.4%, pb0.001; Control vs. G4: 63.4%,
pb0.0001) (Table 3, Fig. 6). In addition, there were signiﬁcant
differences between each HD grade (G2 vs. G3; 35.6%, pb0.001; G3
vs. G4: 21.5%, pb0.01) (Table 3, Fig. 6). Blood buffy coat specimens
showed a signiﬁcant loss of CK-BB levels in both premanifest (22.6%,
pb0.01) and manifest (38.5%, pb0.001) HD patients, with a greater
loss in manifest disease samples (Table 3, Fig. 6). CK-BB immunos-
taining in 50-μm-thick tissue sections conﬁrmed the ﬁndings of
reduced CK-BB levels in HD striatal specimens (Fig. 7). There was
reduced CK-BB immunoreactivity in the HD neostriatum. While
cytosolic CK-BB immunoreactivity was markedly reduced in neurons,
intense CK-BB immunostaining was present in astrocytes in HD tissue
sections (Fig. 7B and D). Combined immunoﬂuorescence for GFAP and
CK-BB immunoreactivities conﬁrmed this observation (Fig. 7E, F and G).
The latter is most likely the consequence of increased reactive astro-
gliosis, a hallmark pathological phenomenon in the neostriatum of HD
subjects [24]. Of note, the expression of CK-BB inmice is predominantly
found in astrocytes and cortical inhibitory neurons in mice [20]. The
expression of CK correlates with L-arginine:glycine amidinotransferase
(AGAT) and guanidinoacetatemethyltransferase (GAMT), two enzymes
responsible for creatine biosynthesis [20]. As such, any alteration in
these enzymes in HD may impact disease expression. In patients with
GAMT and AGAT mutations, clinical symptoms include mental and
motor retardation, extra-pyramidal symptoms, and seizures [26,27].
Braissant and colleagues [28] have recently suggested that there is a
dissociation between GAMT and AGAT activities in neurons, with only
GAMT expression in the neostriatum. A GAMT deﬁciency may result in
reduced CK and creatine deﬁciencies in HD, with subsequent impaired
energetics and neurodegeneration.Table 2
Data analysis of brain and blood samples from 140 CAG HD mice measuring Ck-BB levels.
Months Brain
140 CAG ± WT ± pb0.0
2 0.643 0.035 0.712 0.029 0.069
4 0.688 0.051 0.83 0.021 0.013
6 0.653 0.056 0.928 0.02 0.005
8 0.639 0.047 0.895 0.028 0.009
12 0.541 0.04 0.931 0.021 0.0014. Discussion
Creatine kinase (CK) catalyzes the reversible transfer of a
phosphoryl group from phosphocreatine PCr to adenosine diphos-
phate (ADP), forming adenosine triphosphate (ATP). Thus, creatine
kinase offsets energy depletion by forming PCr, providing a spatialBlood
5 140 CAG ± WT ± pb0.05
0.51 0.042 0.519 0.033 0.431
0.466 0.035 0.567 0.044 0.02
0.433 0.053 0.589 0.018 0.01
0.398 0.061 0.632 0.038 0.001
0.346 0.057 0.617 0.026 0.001
Fig. 4. Open ﬁeld analysis of 140 CAG full-length mutant HDmice from 1 to 6 months. There are signiﬁcant differences in distance traveled (A), resting time (B), ambulatory time (C),
and ambulatory counts (D) starting at 3 months of age. Signiﬁcance was not obtained at 1 and 2 months. *pb0.05.
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energy consumption and, in the reversible reaction, forming PCr and
ADP from creatine and ATP at cellular sites of high-energy phosphate
production (PCr shuttle hypothesis) [29–32]. As such, CK is criticallyFig. 5. CK-BB immunohistochemistry of brain sections through the anterior neostriatum a
immunoreactivity is reduced in the 140 CAGmutant mouse (B), in comparison to the wild typ
tissue section shows a reduction in CK-BB immunoreactivity in the mutant 140 CAGmouse (D
to the wild type littermate control mouse (C). Magniﬁcation bar in A is 2 mm. Magniﬁcatiovital to cellular energy homeostasis and its loss may result in reduced
energy stores and subsequent neuronal dysfunction and death in
HD. It is of interest to note that CK-BB knockout mice present with
pathological sequelae of reduced body and brain weight, atrophiedt the level of the anterior commissure in 140 CAG HD mice at 8 months. Gross CK-BB
e littermate control mouse (A). Higher magniﬁcation within the neostriatum from each
) within both the neuropil and the cytoplasm of striatal neurons (arrows), as compared
n bar in D is 100 μm.
Fig. 6.Western analysis from the medial segment of the caudate nucleus (brain) of age-
matched control patients and Grade 2, Grade 3, and Grade 4 HD patients. There was a
signiﬁcant grade-dependent reduction in CK-BB, with the greatest loss in Grade 4 HD
(Table 3). Blood buffy coat CK-BB analysis from age-matched patient caregivers and
premanifest and manifest HD patients showed a signiﬁcant loss of CK-BB in both
premanifest disease and manifest diseased HD patients, as compared to the controls
(Table 3). Blots are shown under each time point with alpha tubulin controls.
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learning [33,34], all consistent with neurodegenerative effects found
in both HD mouse models and HD patients [1,15,35]. Our results
provide supporting evidence of mitochondrial damage and impaired
energy metabolism in HD [36]. The fact that CK-BB levels are
signiﬁcantly reduced in both brain and peripheral blood buffy coat
samples from HD mice and HD patients at premanifest and manifest
disease stages are of additional signiﬁcance, especially since CK-BB
may be a potential peripheral biomarker for this neurological
disorder.
While it is to be expected that the brain is altered in a neuro-
degenerative disorder, it may not be as obvious that biomarkers of HD
could be found in peripheral tissue samples such as blood, as it is
a central nervous system disorder. For a peripheral biomarker toTable 3
Data analysis of brain and blood samples from HD patients measuring CK-BB levels.
Brain ± pb0.05 Blood ± pb0.05
Controls 1.376 0.068 Controls 0.946 0.057
Grade 2 0.995 0.102 0.04 Premanifest 0.732 0.088 0.01
Grade 3 0.641 0.139 0.001 Manifest 0.581 0.018 0.001
Grade 4 0.503 0.196 0.0001represent the “state” of HD, it would either have to be derived from
the brain or represent pathology occurring in the periphery. The
mutant huntingin protein is expressed ubiquitously throughout the
body, including blood, and may cause detectable, but clinically silent
changes in gene expression and biochemistry anywhere [35]. It is
important to understand what relation potential peripheral biomar-
kers would have to neurodegeneration in the brain. By using HD mice
in these studies, we examined complementary processes in the brain
and periphery with much greater precision and much greater control
of post-mortem and other technical factors associated with human
tissue sampling. The present ﬁndings suggest that CK-BB levels could
serve as a biomarker of disease progression in premanifest and in
manifest disease HD patients. We are currently further investigating
CK-BB levels in blood samples from human clinical trials in HD
patients to assess its potential as a pharmacodynamic marker.
Although tremendous efforts have been made in recent years to
identify early genetic, clinical, and biochemical biomarkers that
indicate the presence of disease prior to the onset of clinical
expression in neurodegenerative disorders, speciﬁc biomarkers for
premanifest HD are very limited at the present time [37]. We have,
however, characterized one biomarker, 8-hydroxy-2'-deoxyguano-
sine (a marker of DNA oxidation), in urine, blood, and brain in
manifest HD patients with correlation in HDmice that acts as amarker
of disease progression and therapeutic efﬁcacy [38–40]. Elevated
central and peripheral levels of 8-hydroxy-2'-deoxyguanosine are not
speciﬁc to HD. Others and we have found elevated levels of
8-hydroxy-2'-deoxyguanosine in other neurodegenerative disorders
and experimental models of neurological diseases, such as amyo-
trophic lateral sclerosis, Parkinson's disease, and Alzheimer's disease
[38,39,41–45]. Similarly, reduced levels of CK-BB are not speciﬁc to
HD alone. We have novel preliminary evidence that CK-BB is also
signiﬁcantly reduced in spinal cord samples and in blood buffy coat
samples from sporadic amyotrophic lateral sclerosis patients.
Biomarkers provide a diagnostic tool to improve early detection of
disease in at-risk individuals and provide greater diagnostic accuracy.
Since there may be a prolonged period of time in which neurons
become dysfunctional before clinical expression of disease, preclinical
detection of biomarkers offers the promise of administering disease-
modifying medications during the premanifest period, further delay-
ing or ameliorating disease symptoms than treatment after disease
onset. CK-BB may act as a “predictor” in deﬁning surrogate endpoints
that substitute for a true clinical outcome endpoint for the purpose of
comparing speciﬁc interventions or treatments in HD clinical trials.
CK-BB may greatly facilitate the accurate evaluation of the effective-
ness of new therapies and improve the safety and efﬁciency of clinical
trials. While CK, also known as creatine phosphokinase (CPK), is often
determined routinely in patients, this blood test is not speciﬁc for the
type or isoenzyme of CK and measures total enzyme activity. Because
CK enzymatic activity is measured under strict conditions of
temperature, pH, substrate concentrations and activators, we are
currently investigating direct assay of CK-BB in blood from HD
patients to conﬁrm the Western analyses.
Amajor advance in studying HD has been the development of both
transgenic and full-length knock-in mouse models that exploit the
mutation shown to underlie HD and replicate the clinical and
neuropathological phenomena observed in HD patients [15,35,46].
One complementary research strategy has been to perform parallel
correlative studies in human and animal models of disease in order to
take advantage of advances being made in animal models and to best
understand the most effective therapeutic strategies. Although logical
and attractive, the validity of this approach remains to be proven. The
HD mice have, however, identiﬁed a growing number of potential
therapies that are in early phase human trials [1,47]. Genetic animal
models of inherited neurological diseases provide an experimentally
accurate system to identify the basis of molecular pathogenesis and
provide an opportunity to test potential treatments and explore their
Fig. 7. CK-BB immunohistochemistry in the medial caudate nucleus from age-matched non-diseased control (A and C) and Grade 3 HD patient. There is marked loss of CK-BB
immunoreactivity in HD (B and D), as observed in both low and high power magniﬁcation. CK-BB immunoreactivity is reduced within both the neuropil and the cytoplasm of striatal
neurons (arrows), as compared to the control patient (A and C), with intense immunostaining in astrocytes in the HD specimen (asterisk in D). Combined GFAP and CK-BB
immunoﬂuorescence in the striatum from the same Grade 3 HD patient shows deﬁnitive colocalization of these proteins in astrocytes. Two-dimensional analysis showed overlap of
each of the antisera [GFAP, green (E); CK-BB. Red (F); and merged ﬁgures (G)]. Magniﬁcation bar in A is 100 μm. Magniﬁcation bar in E is 50 μm.
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transgenic fragment models and full-length knock-in models of HD
share features with human HD [15], the degree of similarity to human
HD increases the closer the model reproduces the exact genetic
conditions for HD. As such, the full-length knock-in HD mice may
provide the best possible molecular genetic comparability to human
HD, especially prior to disease onset. The fulminant and early ex-
pression of disease in the R6/2 mice may not clearly estimate the
degree of premanifest and early symptomatic identiﬁcation of
biomarkers, although others also report very early clinical phenomena
in the full-length 140 CAG HD mice [25]. It is of interest to note,
however, while the CK-BB levels were not signiﬁcantly reduced in the
140 CAGmice at 2 months, there was a signiﬁcant loss of CK-BB levels
in premanifest HD patients.
Strong evidence supports the importance of the creatine kinase
system and speciﬁc isoenzymes in neurodegenerative diseases [48,49]
and the neuroprotective effect of creatine supplementation in studies of
HD, amyotrophic lateral sclerosis, Parkinsonism, brain ischemia, and
other neurological conditions [50]. Creatine is involved in regulating the
octameric form of creatine kinase and decreasesmitochondrial swelling
when inhibitors of creatine kinaseoctamer–dimer transition are present
[49,51]. Reduced creatine stores in HD may precipitate altered creatine
kinase levels [50]. Energy is critical to the biological and molecular
regulation ofmultiple cellular functions. As such, reduced energy levels,
as a consequence of creatine kinase dysfunctionor loss, threaten cellular
homeostasis and integrity, resulting in subsequent neuronal death [48].
The present ﬁndings support the involvement of the creatine kinase
system in HD. We have evidence that chronic high-dose creatine
supplementation in both R6/2 and 140 CAG HD mice normalizes the
reduced levels of CK-BB in both brain and blood buffy coat specimens in
manifest disease (unpublished data). The present ﬁndings justify the
ongoing clinical trials using high-dose creatine in HD patients.
Interestingly, the neuroprotective effects of creatine may be creatine
kinase isoenzyme-dependent, since creatine administration does notinhibit the mitochondrial transition pore in brain mitochondria with
native mitochondrial creatine kinase [51,52].
Correlative analyses in brain and blood in both mice and man
provide a powerful strategy for identifying potential peripheral
biomarkers for HD. The present ﬁndings support the hypothesis of
impaired energy metabolism in HD, identify a speciﬁc mechanism of
energy compromise in the reduction of CK-BB, establish CK-BB as a
potential biomarker of both central and peripheral premanifest and
manifest disease, and provide further rationale for creatine as a
potential neuroprotective treatment for HD.Acknowledgments
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